Maravai LifeSciences (NASDAQ:MRVI) reported first-quarter fiscal 2026 results that management said marked a “strong start to 2026,” driven by growth at its TriLink segment, steady contribution from...
First quarter 2026 total revenue up 41% from prior year Base revenue excluding revenue for high-volume CleanCap for commercialized COVID-19 vaccines up 10% from prior...
Barchart Research What to Expect from MRVI Earnings MRVI Generated May 6, 2026 Current Price $3.94 EPS Estimate $$-0.07 Consensus Rating Moderate Buy Average Move 13.65% Can Maravai's Restructuring Actually...
Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2026 financial...
Organizational restructuring and operating cost reduction ahead of plan Focus on operational excellence, revenue growth, and improving Adjusted EBITDA
Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full...
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference...
Organizational restructuring and operating cost reduction initiatives on track
Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2025 financial...
Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which excludes revenue...